Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04126408 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of Non-invasive Vagus Nerve Stimulation in the Treatment of Headache in Subarachnoid Hemorrhage

A NA study, sponsored by Northwell Health.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT04126408 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04126408, a NA study, has completed, sponsored by Northwell Health.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

This is a single site, randomized, sham-controlled, double blinded pilot study assessing the feasibility, safety, tolerability, and efficacy of non-invasive VNS (nVNS), gammaCore, in the treatment of headache in subarachnoid hemorrhage (SAH). 40 participants will be enrolled, 20 in the active device arm and 20 in the sham arm. The primary efficacy outcome is the the difference between the active and sham treatment groups in morphine equivalence dosage.

Interventions

  • DEVICE gammaCore

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-01-13
Est. Completion 2022-06-20
Phase NA

Sponsor

Northwell Health

370 total trials

What the Registry Record Tells You About NCT04126408

The ClinicalTrials.gov registry entry for NCT04126408 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which gammaCore is the first listed.

NCT04126408 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04126408 about?

NCT04126408 is a clinical study titled "Safety and Efficacy of Non-invasive Vagus Nerve Stimulation in the Treatment of Headache in Subarachnoid Hemorrhage". This is a single site, randomized, sham-controlled, double blinded pilot study assessing the feasibility, safety, tolerability, and efficacy of non-invasive VNS (nVNS), gammaCore, in the treatment of headache in subarachnoid hemorrhage (SAH). 40 participants will be enrolled, 20 in the active device...

What is the current status of trial NCT04126408?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2020-01-13. Estimated completion is 2022-06-20.

What interventions are being tested in trial NCT04126408?

The interventions under investigation include: gammaCore (DEVICE).

Who is sponsoring clinical trial NCT04126408?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.